Oberkochen, Germany | ZEISS Group The ZEISS Ventures portfolio continues to grow in the life science space with the investment in ZOMP, an early-stage start-up based in Cambridge, UK, developing a 3D imaging flow cytometer that enables highly accurate quantitative imaging of millions of cells in a single experiment. The ZEISS Ventures portfolio continues to […]
Indee Labs to complete the development and launch of Hydropore RUO and Cell Therapy along with a direct DNA knock-in kit, enabled by BroadOak’s strategic investment and domain expertise. BERKELEY, Calif. — Indee Labs, the developer of Hydropore™ for non-viral intracellular delivery, is partnering with BroadOak Capital Partners, a leading direct investment and advisory firm focused on life science research […]
Strategic investment is closely linked to ZEISS Research Microscopy Solutions and its capabilities in automated, high-resolution imaging and 3D image analysis Oberkochen, Germany | ZEISS Group ZEISS is investing in life science start-up InSphero to further advance the adoption of 3D microtissues in research and drug development. InSphero AG, a pioneer in 3D spheroid and […]
Through AI/ML-enabled platform with a biology-first approach, Genialis looks to propel drug development, diagnostics and treatment planning Boston & Ljubljana, Slovenia – Genialis, a computational precision medicine company unraveling complex biology to find new ways to address disease, today announced it raised more than $13 million in Series A financing to transform the way diseases are […]
Funding led by Biospring Partners with participation from existing investors. BOSTON — Labviva, the AI-driven life sciences digital marketplace that simplifies and scales purchasing processes, announced today that it has secured $20 million in Series A financing led by Biospring Partners, with participation from existing investors Senator Investment Group, B Capital Group, and Glasswing Ventures. […]
SAN DIEGO — Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, issued the following statement in response to a letter from Carl Icahn dated March 24, 2023: Directors and Officers (D&O) insurance and corporate indemnification are standard for Delaware companies, and support directors in making decisions in the best interests of […]
Atrandi Biosciences Secures Funding and Advances Global Commercialization of Next-Gen Single Cell Analysis Technology VILNIUS, Lithuania and DENVER, CO – Backed by international investors, Atrandi Biosciences is establishing a direct team to support customers in the U.S. and advancing the global commercialization of its breakthrough microfluidic and single-cell analysis technologies. Following a €4.5 million funding round […]
LAUSANNE, Switzerland – Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, announced today that it has completed CHF 40M in Series D1 funding. The round was led by Ernst-Göhner Stiftung Beteiligungen (EGSB), and existing investors PHC Holdings Corporation, Swiss Entrepreneurs Fund, OCCIDENT, and Redalpine participated. The funding includes a EUR […]
SAN DIEGO — Illumina, Inc. (Nasdaq: ILMN), a global leader in DNA sequencing and array-based technologies, confirmed today that it has received notice from Icahn Partners LP and certain of its affiliates of their intention to nominate three candidates—two current Icahn employees, Jesse Lynn and Andrew Teno, and one former Icahn employee, Vincent Intrieri—for election to the Board […]
Semaphore is a leading provider of informatics services and laboratory information management systems (LIMS) supporting life science companies Anthony Uzzo, previously co-founder of Core Informatics and VP of R&D for Digital Science at Thermo Fisher Scientific, to join Semaphore Board as Executive Chairman NEW YORK & VICTORIA, British Columbia — Semaphore Solutions today announced a […]
Pay Invoice
Latest Blogs
-
SDi Predicts a Recovery Amid Headwinds
July 24, 2026 2:51 pm
-
EU Roadmap Provides Further Impetus for New Approach Methodologies
June 29, 2026 12:56 pm
-
MOBILion Expands into Proteomics MS Market
April 30, 2026 5:05 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
